Searchable abstracts of presentations at key conferences in endocrinology

ea0073s13.3 | Symposium 13: TGF-β signalling in ovaries in women with PCOS | ECE2021

Cell-specific expression of TGF-β family members in follicles of women with and without PCOS

Bøtkjær Jane Alrø

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, affecting 5 – 10% of women of reproductive age, and is the major cause of anovulatory infertility. The mechanisms of reproductive dysfunction in PCOS remain to be clarified. Members of the TGF-β and IGF signalling pathway have been suggested to be involved in aberrant follicle development in women with PCOS. This talk will focus on previous and ongoing research that we carried out in Denmark and the Un...

ea0095p18 | Diabetes 1 | BSPED2023

Acceptability of a general population childhood type 1 diabetes screening programme: a qualitative study – T1 Early

Scudder Claire , Townson Julia , Bowen-Morris Jane , Evans Philip , Jones Sarah , Thomas Nick , Stanford Jane , Fox Robin , Todd John , Greenfield Sheila , Gillespie Kathleen , Dayan Colin , Besser Rachel

Background: General population screening for type 1 diabetes (T1D) using islet autoantibodies (IAb) is gaining international momentum, since screening reduces diabetic ketoacidosis, hospitalisation and identifies individuals eligible for future preventative treatments. Qualitative studies have only been undertaken in at-risk individuals (1). We therefore aimed to explore parents’ experiences of their child taking part in a general population T1D screening...

ea0077p164 | Bone and Calcium | SFEBES2021

Resolution of primary hyperparathyroidism following parathyroid adenoma infarction on treatment with cinacalcet

Elford Jane , Head Simeon , Wood Ffion , Williams Elin , Tellier Genevieve , Kraus Alex , Wilton Anthony

Spontaneous resolution of primary hyperparathyroidism following infarction for parathyroid adenomas is rare with infarction on treatment with cinacalcet being even rarer. A 53 year old female who presented to primary care with malaise was found to have biochemical evidence of primary hyperparathyroidism with adjusted calcium 3.31 mmol/l and parathyroid hormone 28.8 pmol/l. Previous medical history was unremarkable. Following discussion with endocrinology, treatment with cinaca...

ea0077p36 | Endocrine Cancer and Late Effects | SFEBES2021

The Impact of COVID-19 on Endocrine Treatments from a Neuroendocrine (NET) patient perspective: homecare and self-injection

Walsh Emma , Ravindiran Abiramie , Paramore Jane , Bates Suzanna , Ibbotson Vicky , Dunkley Kay , Munir Alia

Introduction: The global impact of COVID-19 has been unprecedented. Specific recommendations for the management of neuroendocrine disorders in the pandemic were rapidly released by Endocrine experts. To comply with COVID rules, NET patients, due to attend the endocrine unit in March 2020 for Somatostatin analogue therapy, were rapidly identified. 25 vulnerable patients had urgent domiciliary administration arranged. Other patients were taught to self-inject. Postal surveys wer...

ea0077p216 | Neuroendocrinology and Pituitary | SFEBES2021

Neuroendocrine Tumours (NETS): Telemedicine and patient satisfaction in the COVID-19 pandemic: A patient survey from a European Neuroendocrine Tumour Centre of Excellence

Seneviratne Dilini , Paramore Jane , Bates Suzanne , Ibbotson Victoria , Dunkley Kay , Munir Alia

Introduction: NETs are regarded as rare endocrine malignancies, which often present late. The COVID-19 pandemic may have affected this and patient care. The impact will have been felt in health service delivery and patient experiences. To understand NET patient perspectives and optimise care, we conducted a survey to review patient perception of: telemedicine-based care, delays to imaging, treatment, and the impact of COVID-19.Method: 70 NET patients tre...

ea0077p233 | Reproductive Endocrinology | SFEBES2021

In vitro effects of dihydrotestosterone (DHT) on gonadotropin receptor function and steroidogenesis in human granulosa lutein cells

Anujan Priyanka , Owens Lisa , Alro Botkjaer Jane , Hanyaloglu Aylin , Hardy Kate , Franks Stephen

Polycystic ovary syndrome (PCOS) is a multifactorial, complex endocrine disorder affecting a significant proportion of the global population. Hyperandrogenism is a key feature of PCOS patients. Aberrant secretion and/or action of gonadotropins have been implicated in PCOS, but, to date, we have only limited knowledge of how these factors may interact in the aetiology of PCOS. We hypothesised that excess androgens may cause aberrant gonadotropin activity and therefore sought to...

ea0077p246 | Reproductive Endocrinology | SFEBES2021

The Impact of COVID-19 on Endocrine Treatments from a patient perspective - effect on parenteral testosterone

Walsh Emma , Bates Suzanna , Dunkley Kay , Paramore Jane , Ibbotson Vicky , Munir Alia

Introduction: The COVID-19 pandemic has had a huge impact on the delivery of health services. Here we review the patient perspective, on rapid changes in treatment delivery of testosterone preparations instituted in the first wave of the pandemic.Methods: 49 hypogonadal male patients were identified as attenders to the Endocrine unit for Nebido™ injection. They were temporarily switched to testosterone gel to rapidly comply with COVID rules. 8 weeks...

ea0051p053 | Pituitary and growth | BSPED2017

Growth hormone treatment in a regional centre: licensed and unlicensed indications

Whitehead Mandy , Tseretopoulou Xanthippi , Cottrell-Jane Emily , Alvi Sabah , Mushtaq Talat

Introduction: In the UK, GH therapy is licensed for use in GH deficiency, Turner Syndrome, Small for Gestational Age (SGA), Prader Willi Syndrome (PWS), SHOX deletion and Chronic Renal Failure (CRF). Worldwide there are a number of additional indications. The aim was to review the use of GH prescriptions in relation to indications and to evaluate if there were similarities or differences between the licensed and unlicensed groups.Methods: All children st...

ea0084ps3-12-109 | Graves’ Disease 2 and Orbitopathy | ETA2022

Blocking the TSH receptor with human monoclonal autoantibody K1-70TM in patients with graves’ disease – results from a phase 1 clinical trial

Furmaniak Jadwiga , Sanders Jane , Sanders Paul , Li Yang , Rees Smith Bernard

Objectives: TSH receptor (TSHR) autoantibodies (TRAb) which mimic the actions of TSH are responsible for hyperthyroidism in Graves’ disease (GD) which is often associated with Graves’ orbitopathy (GO). K1-70 is a TSHR specific human monoclonal autoantibody which binds to the TSHR with high affinity and prevents stimulation of the TSHR by TSH and TRAb. Safety, tolerability, pharmacokinetic, pharmocodynamic and immunogenic effects of K1-70 in patients with GD were asse...

ea0085p9 | Bone | BSPED2022

Bone biochemistry in children with fractures presenting with non-accidental injury

McDonald Heather , Forbes Owen , Lucas-Herald Angela , Houston James , McDevitt Helen , McNeilly Jane , Mason Avril

Background: Fractures are reported in 1/3 of children who have been abused. The Royal College of Paediatrics and Child Health (RCPCH) recommends that assessment of fractures where there is suspicion of physical abuse should include bone biochemistry: calcium (Ca), phosphate (Ph), alkaline phosphatase (ALP), parathyroid hormone (PTH) and Vitamin D (VitD).Objectives: To describe the pattern of bone biochemistry in children with fractures when non-accidenta...